Active Ingredient History
NEO 212 is novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. NEO212 is a conjugate of temozolomide (TMZ,) with the natural product perillyl alcohol (POH). NEO 212 causes DNA damage and cell death much more efficiently than TMZ because linkage with POH increased it's biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (approved 1999)
Glioblastoma (approved 1999)
Adenocarcinoma (Phase 2)
Adolescent (Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Astrocytoma (Phase 3)
Biliary Tract Neoplasms (Phase 2)
Bone Neoplasms (Phase 2)
Brain Diseases (Phase 1)
Brain Neoplasms (Phase 4)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 2)
Cannabis (Phase 2)
Capecitabine (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Large Cell (Phase 2)
Carcinoma, Merkel Cell (Phase 1/Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Small Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Central Nervous System Diseases (Phase 2)
Central Nervous System Neoplasms (Phase 2)
Child (Phase 2)
Choriocarcinoma (Phase 1)
Choroid Plexus Neoplasms (Phase 3)
Chromosome Aberrations (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Craniopharyngioma (Phase 1)
Cytokine-Induced Killer Cells (Phase 4)
Cytomegalovirus Infections (Phase 1/Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
Diarrhea (Phase 1)
Diffuse Intrinsic Pontine Glioma (Phase 3)
Disease Progression (Phase 1)
DNA Mismatch Repair (Phase 1)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 1)
Frailty (Phase 2)
Gallbladder Neoplasms (Phase 1/Phase 2)
Ganglioneuroblastoma (Phase 3)
Gastrinoma (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
General Surgery (Phase 2)
Germinoma (Phase 1)
Glioblastoma (Phase 4)
Glioma (Phase 4)
Gliosarcoma (Phase 3)
Glucagonoma (Phase 2)
Hamartoma (Phase 1)
Head and Neck Neoplasms (Phase 2)
Hedgehog Proteins (Phase 1/Phase 2)
Hematoma, Subdural (Phase 2)
Hepatoblastoma (Phase 1/Phase 2)
Immunologic Factors (Phase 1/Phase 2)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 1)
Kidney Neoplasms (Phase 1/Phase 2)
Leiomyosarcoma (Phase 2/Phase 3)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2/Phase 3)
Melanoma (Phase 3)
Meninges (Phase 1)
Meningioma (Phase 1)
Meningitis (Phase 1)
Mesothelioma (Phase 1)
Microsatellite Instability (Phase 2)
Multiple Endocrine Neoplasia Type 1 (Phase 1)
Multiple Endocrine Neoplasia Type 2a (Phase 1)
Multiple Endocrine Neoplasia Type 2b (Phase 1)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neoplasms, Bone Tissue (Phase 3)
Neoplasms by Histologic Type (Phase 3)
Neoplasms, Connective and Soft Tissue (Phase 3)
Neoplasms, Connective Tissue (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 1/Phase 2)
Neoplasms, Nerve Tissue (Phase 1/Phase 2)
Neoplasms, Neuroepithelial (Phase 3)
Neoplasms, Second Primary (Phase 2)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 2)
Neuroectodermal Tumors, Primitive (Phase 1)
Neuroendocrine Tumors (Phase 4)
Neurofibromatosis 1 (Phase 2)
Neuroma, Acoustic (Phase 1)
Oligodendroglia (Phase 2)
Oligodendroglioma (Phase 3)
Optic Nerve Glioma (Phase 3)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 2)
Paraganglioma, Extra-Adrenal (Phase 1)
Pheochromocytoma (Phase 2)
Pinealoma (Phase 2)
Pituitary Neoplasms (Phase 2/Phase 3)
Poly(ADP-ribose) Polymerase Inhibitors (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Radiation Oncology (Phase 2)
Radiotherapy (Phase 3)
Rare Diseases (Phase 3)
Rectal Neoplasms (Phase 2)
Recurrence (Phase 3)
Retinoblastoma (Phase 2)
Rhabdoid Tumor (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 3)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2/Phase 3)
Somatostatinoma (Phase 2)
Spinal Cord Neoplasms (Phase 2/Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Stomach Neoplasms (Phase 2)
Supratentorial Neoplasms (Phase 1)
Temozolomide (Phase 3)
Testicular Neoplasms (Phase 2)
Therapeutic Equivalency (Phase 1)
Thymoma (Phase 1)
Thyroid Neoplasms (Phase 1)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Vaccination (Phase 2)
Vaccines (Phase 1/Phase 2)
Wilms Tumor (Phase 2)
Zollinger-Ellison Syndrome (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
